Shares in Novocure (NSDQ:NVCR) fell today after the oncology company missed expectations on Wall Street with its second quarter results.
The St. Helier, N.J.-based company reeled in its losses to -$21.2 million on sales of $38.4 million for the 3 months ended June 30, for bottom-line growth of 48% on sales growth of 114% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.